Navigation Links
NuVasive Completes Acquisition of Osteocel Biologics Business
Date:7/24/2008

l continue to supply Osteocel to NuVasive for a period of 18 months following the closing, and will be eligible to receive up to a total of $22.5 million (in cash or stock) in milestones related to product supply. NuVasive will also make a payment of $15 million (in cash or stock) upon achieving Osteocel sales of $35 million. Lastly, the dedicated processing facility for Osteocel will be transferred to NuVasive at the end of the 18 month supply period and NuVasive will make a payment of up to $12.5 million (in cash or stock) at that time. The total maximum consideration is $85 million.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if the
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
2. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
3. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
4. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
7. NuVasive to Host Investor Reception on September 11, 2007
8. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
9. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
10. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
11. Accuri Cytometers Completes $13 Million Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 Can economic ... from work motivate members of the public to increase ... including Johns Hopkins Carey Business School Assistant ... yes. Pointing to a large body of recent research ... the May 24, 2013, issue of Science that the ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
(Date:5/23/2013)... , May 23, 2013 Pressure BioSciences, Inc. ... the Company will host a teleconference to discuss its ... business update. The teleconference information is provided below: ... Eastern Daylight Time (EDT) Dial-in: (800) 875-3456 ... 607-2001 (Int,l) Passcode: VS22823 For those unable ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... 2 Accera, Inc., a biotechnology ... (CNS) diseases, today launched Axona(TM) in the United ... first-in-class medical food for the clinical dietary management ... Dispensed by prescription, it targets the metabolic deficiencies ...
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ... new Senior Secured Term Loan and Revolving Credit Facility. ... agent and lender for both the Term Loan and ... draw secured term loan facility of up to $10 ...
... Inc.,(Nasdaq: BNVI ) today announced the online ... Menerba(TM) (formerly MF101) is,well tolerated, safe and effective for ... associated with menopause. , The ... safety and,efficacy of two doses of Menerba versus placebo. ...
Cached Biology Technology:Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 2Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 3Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 4Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 4Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 2Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 3Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 4
(Date:5/24/2013)... the immune system to combat metastatic cancer , ... destruction by the immune system. Stimulation of the immune ... are many factors that cause the immune system to ... that function to suppress the immune system response. In ... , researchers led by Ronald Levy at Stanford University ...
(Date:5/24/2013)... microRNAs (miRNAs) and other non-coding RNAs are small ... proteins. In recent years they have emerged as ... establish tissue origin for cancers of unknown primary ... for disease, but clinically tractable, diagnostic methods for ... currently available. In this issue of the ...
(Date:5/24/2013)... medication against Alzheimer,s disease, scientists have focused among other ... (A-beta). After all, it is the accumulation of A-beta that ... Starting point for the formation of A-beta is APP. Alessia ... unravel the function of APPL the fruit-fly version of ... , Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A new strategy required in the search for Alzheimer's drugs? 2
... and scientific experts propose a global framework for the ... including further clinical testing In Australia. The South-Pacific ... anxiety but is restricted in some countries. Leading ... of Melbourne, Australia; Professor Rolf Teschke from Wolfgang Goethe-University, ...
... have made a significant discovery about the nature of ... Tanner, BDS, Ph.D., identified a new pathogen connected to ... wiggsiae , was present in the mouths of children ... such as Streptococcus mutans were not detected. ...
... especially for the excellence of its peacekeepers and ice ... to help countries elsewhere brace for drought, flood and ... year horizon. Within a single generation, recent studies ... by an estimated 40%, with one-third of humanity having ...
Cached Biology News:Experts propose global guidelines for safe use of Kava and new Australian study 2Forsyth team gains new insight on childhood dental disease 2Canada's role grows amid looming world water shortages in some places, more flooding in others 2Canada's role grows amid looming world water shortages in some places, more flooding in others 3Canada's role grows amid looming world water shortages in some places, more flooding in others 4Canada's role grows amid looming world water shortages in some places, more flooding in others 5Canada's role grows amid looming world water shortages in some places, more flooding in others 6Canada's role grows amid looming world water shortages in some places, more flooding in others 7
Lipid Phosphate Phosphohydrolase 2...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: